• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4607199)   Today's Articles (2307)   Subscriber (49374)
For: Feldman BM, Berger K, Bohn R, Carcao M, Fischer K, Gringeri A, Hoots K, Mantovani L, Willan AR, Schramm W. Haemophilia prophylaxis: how can we justify the costs? Haemophilia 2012;18:680-4. [PMID: 22507524 DOI: 10.1111/j.1365-2516.2012.02790.x] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Number Cited by Other Article(s)
1
Zimmermann BM, Eichinger J, Baumgartner MR. A systematic review of moral reasons on orphan drug reimbursement. Orphanet J Rare Dis 2021;16:292. [PMID: 34193232 PMCID: PMC8247078 DOI: 10.1186/s13023-021-01925-y] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2021] [Accepted: 06/20/2021] [Indexed: 01/22/2023]  Open
2
Mareque M, Mingot-Castellano ME, López-Fernández MF, Álvarez-Román MT, Oyagüez I. Prophylaxis therapy with bypassing agents in patients with haemophilia A and inhibitors undergoing surgery: A cost analysis in Spain. Eur J Haematol 2020;105:94-100. [PMID: 32220097 PMCID: PMC7383573 DOI: 10.1111/ejh.13414] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2019] [Revised: 03/18/2020] [Accepted: 03/19/2020] [Indexed: 01/19/2023]
3
Martin AP, Burke T, Asghar S, Noone D, Pedra G, O'Hara J. Understanding minimum and ideal factor levels for participation in physical activities by people with haemophilia: An expert elicitation exercise. Haemophilia 2020;26:711-717. [PMID: 32268007 DOI: 10.1111/hae.13985] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2019] [Revised: 03/11/2020] [Accepted: 03/12/2020] [Indexed: 12/23/2022]
4
What is the role for population pharmacokinetics in hemophilia? ACTA ACUST UNITED AC 2017. [DOI: 10.4155/ipk-2016-0018] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
5
Miners AH, Krishnan S, Pasi KJ. Predicting the outcomes of using longer-acting prophylactic factor VIII to treat people with severe hemophilia A: a hypothetical decision analysis. J Thromb Haemost 2016;14:2141-2147. [PMID: 27510890 DOI: 10.1111/jth.13440] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2015] [Indexed: 01/19/2023]
6
Orkin SH, Reilly P. Paying for future success in gene therapy. Science 2016;352:1059-61. [DOI: 10.1126/science.aaf4770] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
7
Gringeri A, Doralt J, Valentino LA, Crea R, Reininger AJ. An innovative outcome-based care and procurement model of hemophilia management. Expert Rev Pharmacoecon Outcomes Res 2016;16:337-45. [PMID: 27074697 DOI: 10.1080/14737167.2016.1178066] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
8
de Moerloose P, Arnberg D, O'Mahony B, Colvin B. Improving haemophilia patient care through sharing best practice. Eur J Haematol 2015;95 Suppl 79:1-8. [DOI: 10.1111/ejh.12630] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/26/2015] [Indexed: 02/05/2023]
9
Villarrubia R, Oyagüez I, Álvarez-Román MT, Mingot-Castellano ME, Parra R, Casado MA. Cost analysis of prophylaxis with activated prothrombin complex concentrate vs. on-demand therapy with activated factor VII in severe haemophilia A patients with inhibitors, in Spain. Haemophilia 2015;21:320-329. [DOI: 10.1111/hae.12681] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/28/2015] [Indexed: 11/29/2022]
10
De Rueda B, Santa Catalina S, Lucia F, García de la Calzada D, Aguilar C. A new case of bacterial endocarditis in a child with severe Haemophilia A carrying a central venous access device. Haemophilia 2015;21:e251-e253. [PMID: 25754032 DOI: 10.1111/hae.12658] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/19/2015] [Indexed: 11/29/2022]
11
de Almeida AM, de Rezende MU, Cordeiro FG, Villaça PR, D'Amico EA, Hernandez AJ, Camanho GL. Arthroscopic partial anterior synovectomy of the knee on patients with haemophilia. Knee Surg Sports Traumatol Arthrosc 2015;23:785-91. [PMID: 25839071 DOI: 10.1007/s00167-013-2706-6] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
12
Polack B, Calvez T, Chambost H, Rothschild C, Goudemand J, Claeyssens S, Borel‐Derlon A, Bardoulat I, Maurel F, Woronoff‐Lemsi M. EQOFIX: a combined economic and quality‐of‐life study of hemophilia B treatments in France. Transfusion 2015;55:1787-97. [DOI: 10.1111/trf.13016] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2014] [Revised: 12/03/2014] [Accepted: 12/08/2014] [Indexed: 10/24/2022]
13
Farrugia A, Cassar J, Kimber MC, Bansal M, Fischer K, Auserswald G, O'Mahony B, Tolley K, Noone D, Balboni S. Treatment for life for severe haemophilia A- A cost-utility model for prophylaxis vs. on-demand treatment. Haemophilia 2013;19:e228-38. [DOI: 10.1111/hae.12121] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/10/2013] [Indexed: 02/06/2023]
14
Yan YH, Kung CM. Investigated the hospital utilization and medical resource usage of haemophilia A and B in Taiwan: 2001-2010. Health (London) 2013. [DOI: 10.4236/health.2013.510a1001] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA